HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia.

Abstract
Fourteen patients with refractory acute non-lymphocytic leukemia were entered into a dose-seeking trial of combination therapy with etoposide and amsacrine given daily for five consecutive days. There were three complete responses lasting 2 months, 3 months, and 10 months and two transient partial remissions. Dose-limiting toxicities were stomatitis and diarrhea. Prolonged aplasia occurred at the highest doses tested and appeared to result from repetitive doses of the combination given as maintenance. We recommend for induction and consolidation/intensification treatment VP-16, 125 mg/m2, and AMSA, 125 mg/m2, intravenously daily for 5 days. A reduction by at least 50% in the dose of each drug is recommended for maintenance of complete remissions.
AuthorsL Letendre, V Hinemann, H C Hoagland, J S Kovach
JournalMedical and pediatric oncology (Med Pediatr Oncol) Vol. 13 Issue 4 Pg. 232-4 ( 1985) ISSN: 0098-1532 [Print] United States
PMID3839284 (Publication Type: Journal Article)
Chemical References
  • Aminoacridines
  • Antineoplastic Agents
  • Amsacrine
  • Etoposide
Topics
  • Acute Disease
  • Adult
  • Aged
  • Aminoacridines (administration & dosage)
  • Amsacrine
  • Antineoplastic Agents (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Dose-Response Relationship, Drug
  • Drug Evaluation
  • Drug Resistance
  • Etoposide (administration & dosage)
  • Female
  • Humans
  • Leukemia (drug therapy)
  • Liver Function Tests
  • Male
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: